CA3067276A1 - Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia - Google Patents

Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia Download PDF

Info

Publication number
CA3067276A1
CA3067276A1 CA3067276A CA3067276A CA3067276A1 CA 3067276 A1 CA3067276 A1 CA 3067276A1 CA 3067276 A CA3067276 A CA 3067276A CA 3067276 A CA3067276 A CA 3067276A CA 3067276 A1 CA3067276 A1 CA 3067276A1
Authority
CA
Canada
Prior art keywords
cells
pll
treatment
tinostamustine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067276A
Other languages
English (en)
French (fr)
Inventor
Thomas Jorg MEHRLING
Marco HERLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CA3067276A1 publication Critical patent/CA3067276A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3067276A 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia Pending CA3067276A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709402.0A GB201709402D0 (en) 2017-06-13 2017-06-13 Compounds for treating t-pll
GB1709402.0 2017-06-13
PCT/EP2018/065664 WO2018229132A1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia

Publications (1)

Publication Number Publication Date
CA3067276A1 true CA3067276A1 (en) 2018-12-20

Family

ID=59358363

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067276A Pending CA3067276A1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia

Country Status (14)

Country Link
US (3) US11318117B2 (OSRAM)
EP (1) EP3638231B1 (OSRAM)
JP (1) JP7195283B2 (OSRAM)
KR (1) KR102655833B1 (OSRAM)
AR (1) AR112101A1 (OSRAM)
AU (1) AU2018285821B2 (OSRAM)
BR (1) BR112019026484A2 (OSRAM)
CA (1) CA3067276A1 (OSRAM)
ES (1) ES2966954T3 (OSRAM)
GB (1) GB201709402D0 (OSRAM)
IL (1) IL271017A (OSRAM)
MX (1) MX392103B (OSRAM)
TW (1) TW201919616A (OSRAM)
WO (1) WO2018229132A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
JP2022522928A (ja) * 2018-12-18 2022-04-21 ムンディファーマ・インターナショナル・コーポレーション・リミテッド 多発性骨髄腫を治療するための化合物
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
PT986403E (pt) 1997-06-13 2004-04-30 Cydex Inc Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US20020076409A1 (en) 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
JP4790594B2 (ja) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
WO2005013958A1 (en) 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2005230682B2 (en) 2004-04-05 2010-10-21 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EA023400B1 (ru) 2005-05-13 2016-05-31 Топотаргет Юкей Лимитед Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов
CA2673483C (en) 2006-10-20 2014-04-08 Icos Corporation Compositions of chk1 inhibitors
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009067453A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
EP2346836B1 (en) 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
SI2389375T1 (sl) 2009-01-23 2015-11-30 Euro-Celtique S.A. Derivati hidroksamske kisline
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
ES2605586T3 (es) 2010-04-16 2017-03-15 Cellact Pharma Gmbh Análogos de etopósido para el tratamiento de tumores metastásicos
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
PL2760860T3 (pl) 2011-09-28 2017-06-30 Euro-Celtique S.A. Pochodne iperytu azotowego
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CA2969790A1 (en) 2014-12-05 2016-06-09 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
CN106580971B (zh) 2015-10-20 2019-11-12 杭州梯诺医药科技有限公司 一种药物组合物及其制备方法
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
JP2022522928A (ja) 2018-12-18 2022-04-21 ムンディファーマ・インターナショナル・コーポレーション・リミテッド 多発性骨髄腫を治療するための化合物

Also Published As

Publication number Publication date
KR102655833B1 (ko) 2024-04-08
WO2018229132A1 (en) 2018-12-20
JP7195283B2 (ja) 2022-12-23
IL271017A (en) 2020-01-30
EP3638231C0 (en) 2023-12-20
ES2966954T3 (es) 2024-04-25
MX392103B (es) 2025-03-21
US11918558B2 (en) 2024-03-05
US20200113871A1 (en) 2020-04-16
EP3638231B1 (en) 2023-12-20
BR112019026484A2 (pt) 2020-07-14
AU2018285821B2 (en) 2024-07-04
US11318117B2 (en) 2022-05-03
AU2018285821A1 (en) 2019-12-19
GB201709402D0 (en) 2017-07-26
MX2019015208A (es) 2022-05-03
JP2020523359A (ja) 2020-08-06
EP3638231A1 (en) 2020-04-22
KR20200015563A (ko) 2020-02-12
US20220401417A1 (en) 2022-12-22
TW201919616A (zh) 2019-06-01
US20240316009A1 (en) 2024-09-26
AR112101A1 (es) 2019-09-18
US12370178B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
US12370178B2 (en) Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
CN103501785B (zh) 用于治疗脑肿瘤的csf-1r抑制剂
US10918638B2 (en) Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
US11337983B2 (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
CN107106580B (zh) 治疗癌症干细胞的组合物
US10736895B2 (en) Cerdulatinib for treating hematological cancers
KR20200014790A (ko) 난소암의 치료에 사용되는 티노스타무스틴
EP3220908B1 (en) Compositions and methods for treating endometriosis
US20240197904A1 (en) Combination therapy for treating glioblastoma
US20240025959A1 (en) Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230425

EEER Examination request

Effective date: 20230425

EEER Examination request

Effective date: 20230425

EEER Examination request

Effective date: 20230425